These results suggested that sequential changes in the serum concentrations of CD147 and MMP-9 could be beneficial for assessing chemotherapy outcome (i.e., CR/PR/SD or PD) in patients with NSCLC. Here, MMP9 is linked to non-small cell lung carcinoma.